Extravasations can cause pain, swelling, redness, blistering, peeling, tissue sloughing, and necrosis. Although rare, ...

Noting other prostate cancer disparities between rural and urban men in the US, investigators assessed biochemical recurrence.

Researchers tested the efficacy and safety of zanubrutinib plus venetoclax as treatment for CLL/SLL depending on 17p deletion and TP53 mutation status.

Results of a prospective study demonstrated significant associations between pretransplant SIR measurements and clinical outcomes in patients undergoing alloHCT.

A review of emails between nurse liaisons and multisite researchers and nurses described the liaison’s essential role in communications across all participants.

Persons in the highest quartile of morphine milligram equivalents exposure have increased risk for new persistent opioid use.

These insights may inform personalized treatment strategies in which microbiome composition could serve as a biomarker to guide therapy selection,” the researchers wrote.

Biomarker testing rates before first-line treatment increased over time, and rates of biomarker testing increased between first-line and second-line treatment.

If confirmed, our findings may provide a more precise clinical target for definitive trials of PA as a prostate cancer treatment as well as for PA promotion efforts in newly diagnosed prostate cancer ...

Between 2006 and 2017, the percentage of patients with CLL/SLL receiving first-line treatment within 3 years of diagnosis ...

Elevated interleukin-6 (IL-6) levels and increased density of regulatory T-cells (Tregs) in the tumor microenvironment (TME) were associated with poorer survival outcomes in chronic lymphocytic ...

Results from the TALENTACE trial suggest that atezolizumab plus bevacizumab and on-demand TACE may be a “new and effective treatment option,” according to Guohong Han, MD, PhD.